The OctavaColon tests are qualitative plasma tests that are indicated to people above 18 years of age suspected with colon abnormality. The blood tests will provide additional information to the doctor in the course of colon cancer diagnosis for both normal population and high risk population
The clinical objective of this study is to develop two antibody-based blood tests for additional information during colon cancer diagnosis - 1. Highly specific (OctavaGold) - provides additional information to doctors during evaluation of normal population. 2. Highly sensitive (OctavaSilver) - provides additional information to doctors during evaluation of high risk population. The study will be considered successful it can achieve at least one of the following sets of performances - 1. For the OctavaGold - 95% specificity with at least 50% sensitivity. 2. For the OctavaSilver - 95% sensitivity with at least 50% specificity. The biological objective of this study is to find the best set of antigens, that when combined with the appropriate algorithm will support each of the above clinical objectives
Study Type
OBSERVATIONAL
Enrollment
1,080
Soroka Medical Center
Beersheba, Israel
NOT_YET_RECRUITING"Carmel" Medical Center
Haifa, Israel
NOT_YET_RECRUITINGSheba Tel hashomer
Ramat Gan, Israel
RECRUITINGNumber of participants in each of the clinicaly defined groups (0,1 and 2).
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.